Cellectis’ Shareholders Meeting to be Held on December 22, 2023
November 17, 2023 16:30 ET
|
Cellectis Inc.
NEW YORK, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop...
Gracell Biotechnologies to Participate in Inaugural Cell Therapy for Autoimmune Disease Summit
November 16, 2023 08:00 ET
|
Gracell Biotechnologies Inc.
Presentation to focus on application of next-generation CAR-T cell therapy technologies for treatment of autoimmune disease Gracell to highlight translational research supporting CD19/BCMA...
CARGO Therapeutics Announces Pricing of Initial Public Offering
November 09, 2023 20:07 ET
|
Cargo Therapeutics, Inc.
CARGO Therapeutics Announce Pricing of IPO
Celyad Oncology reports third quarter 2023 financial results and recent business highlights
November 09, 2023 01:00 ET
|
Celyad Oncology SA
Publication of data detailing the development of our microRNA (miRNA)-based multiplex shRNA approach, which allows to down-regulate several genes simultaneously, in Molecular Therapy – Nucleic...
Gracell Biotechnologies Wins Overall Immunology Solution of the Year by BioTech Breakthrough Awards Program
November 08, 2023 08:30 ET
|
Gracell Biotechnologies Inc.
Third annual BioTech Breakthrough Award recognizes excellence in life science and biotechnology solutions, services and companies GC012F, a FasTCAR-enabled autologous CAR-T cell therapy, is...
Cellectis to Present Preliminary Results of NATHALI_01 and Updated Results of the BALLI_01 Phases I Trials at the American Society of Hematology (ASH) 65th Annual Meeting
November 02, 2023 16:30 ET
|
Cellectis Inc.
NEW YORK, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
Gracell Biotechnologies to Present Updated Results from BCMA/CD19 Dual-Targeting FasTCAR-T GC012F in Newly Diagnosed Multiple Myeloma at the 65ᵗʰ American Society of Hematology Annual Meeting & Exposition
November 02, 2023 09:00 ET
|
Gracell Biotechnologies Inc.
Oral presentation of the updated results from ongoing Phase 1 investigator-initiated study of GC012F in frontline setting for transplant-eligible, high-risk newly diagnosed multiple myeloma ...
Cellectis to Report Third Quarter 2023 Financial Results on November 6, 2023
November 01, 2023 16:30 ET
|
Cellectis Inc.
NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
Cellectis Announces Strategic Collaboration and Investment Agreements with AstraZeneca
November 01, 2023 03:00 ET
|
Cellectis Inc.
Collaboration leverages Cellectis’ gene editing technologies and manufacturing capabilities to develop up to 10 novel cell & gene therapy candidate productsCellectis to receive up to $245M in cash...
Gracell Biotechnologies to Present Data Highlighting Preclinical Efficacy of SMART CART™ Against Solid Tumors at Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
October 31, 2023 09:00 ET
|
Gracell Biotechnologies Inc.
Novel, proprietary technology designed to strengthen the functionality of CAR-T cells against solid tumors SMART CAR-T cells demonstrated resistance to immunosuppressive tumor microenvironment...